A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Clinical Cancer Research|2018Cited by 236
EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasisLechen Li, Kathleen Kelly, Amir H. Ameri et al.|Oncogene|2019Cited by 172
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Berkley E. Gryder et al.|Molecular Cancer Therapeutics|2020Cited by 55
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Kathleen Kelly, Lei Fang et al.|Journal of Clinical Investigation|2023Cited by 33
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H. Jansson, Kathleen Kelly, Carleen Klummp-Thomas et al.|Scientific Reports|2018Cited by 33